Carregant...
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more...
Guardat en:
| Publicat a: | Adv Ther |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8004501/ https://ncbi.nlm.nih.gov/pubmed/33620694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01614-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|